| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Gain Therapeutics, Inc. (GANX) has 9 insiders with recent SEC Form 4 filings, including 9 buys and 2 sells. GANX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 200.0K | $356.0K | - | |
| Other | 50.0K | $89.0K | - | |
| Dir | 15.0K | $26.7K | - | |
| Dir | 15.0K | $26.7K | - | |
| Dir | 15.0K | $26.7K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 9, 2024 | Mack Gene | CFO And Interim CEO | Buy | 14,400 | $1.01 | $14,544.00 | New | +127.2% | +50.8% | |
| Aug 9, 2024 | Islam Khalid | Executive Chairman | Buy | 50,000 | $1.00 | $49,940.00 | New | +127.2% | +50.8% | |
| Jul 1, 2024 | Richman Eric I79 | Director | Buy | 17,000 | $1.22 | $20,670.00 | +3.1% | +58.9% | +40.2% | |
| Mar 28, 2024 | Riley Jeffrey Scott | Director | Buy | 30,000 | $3.86 | $115,770.00 | New | -66.3% | -49.9% | |
| Dec 21, 2023 | Alder Matthias | Chief Executive Officer | Sale+OE | 206 | $2.46 | $506.76 | -3.8% | +70.4% | -37.6% | |
| Dec 7, 2023 | Alder Matthias | Chief Executive Officer | Sell | 1,820 | $2.50 | $4,550.00 | -27.3% | +86.9% | -29.0% | |
| May 25, 2022 | Richman Eric I79 | Chief Executive Officer | Buy | 2,482 | $2.58 | $6,403.56 | +1.2% | +28.7% | +74.0% | |
| May 20, 2022 | Richman Eric I79 | Chief Executive Officer | Buy | 13,256 | $2.79 | $37,034.48 | +3.2% | +38.4% | +80.1% | |
| May 19, 2022 | Calabrese Salvatore | Chief Financial Officer | Buy | 3,000 | $8,100.00 | $24,300,000.00 | -100% | +46.3% | +84.1% |